• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Molecular responses in decitabine- and decitabine/ venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes.

作者信息

Gruszczynska Agata, Maiti Abhishek, Miller Christopher A, Ramakrishnan Sai Mukund, Link Daniel C, Uy Geoffrey L, Petti Allegra A, Hayes Kala, DiNardo Courtney D, Ravandi Farhad, Ley Timothy J, Spencer David H, Gao Feng, Konopleva Marina Y, Welch John S

机构信息

Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri 63110.

Department of Leukemia, MD Anderson Cancer Center, Houston, Texas 77030.

出版信息

Haematologica. 2024 Aug 1;109(8):2653-2659. doi: 10.3324/haematol.2022.281396.

DOI:10.3324/haematol.2022.281396
PMID:38618679
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11290502/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e06b/11290502/f8dba24ae421/1092653.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e06b/11290502/9807c99c700b/1092653.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e06b/11290502/f8dba24ae421/1092653.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e06b/11290502/9807c99c700b/1092653.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e06b/11290502/f8dba24ae421/1092653.fig2.jpg

相似文献

1
Molecular responses in decitabine- and decitabine/ venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes.地西他滨和地西他滨/维奈克拉治疗的急性髓系白血病和骨髓增生异常综合征患者的分子反应
Haematologica. 2024 Aug 1;109(8):2653-2659. doi: 10.3324/haematol.2022.281396.
2
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab.使用地西他滨/维奈克拉和达雷妥尤单抗治疗与治疗相关的急性髓系白血病及潜在的多发性骨髓瘤。
Ann Hematol. 2021 Jun;100(6):1637-1640. doi: 10.1007/s00277-021-04490-3. Epub 2021 Mar 13.
3
[Efficacy of selinexor combined with subcutaneous decitabine in myeloid malignancies refractory to or relapsed after venetoclax therapy].塞利尼索联合皮下注射地西他滨治疗对维奈克拉治疗难治或复发的髓系恶性肿瘤的疗效
Zhonghua Xue Ye Xue Za Zhi. 2025 May 14;46(5):473-477. doi: 10.3760/cma.j.cn121090-20240920-00358.
4
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.在未经治疗的老年急性髓系白血病患者中，venetoclax 联合地西他滨或阿扎胞苷的安全性和初步疗效：一项非随机、开放标签、1b 期研究。
Lancet Oncol. 2018 Feb;19(2):216-228. doi: 10.1016/S1470-2045(18)30010-X. Epub 2018 Jan 12.
5
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.10天阿扎胞苷联合维奈克拉用于新诊断的不适合强化化疗以及复发或难治性急性髓系白血病的治疗：一项单中心2期试验
Lancet Haematol. 2020 Oct;7(10):e724-e736. doi: 10.1016/S2352-3026(20)30210-6. Epub 2020 Sep 5.
6
Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia.维奈克拉、FLT3抑制剂和地西他滨三联疗法治疗FLT3突变的急性髓系白血病。
Blood Cancer J. 2021 Feb 1;11(2):25. doi: 10.1038/s41408-021-00410-w.
7
The efficacy and safety of venetoclax combined with decitabine in elderly patients with acute myeloid leukemia: a systematic review and meta-analysis.维奈托克联合地西他滨治疗老年急性髓系白血病患者的疗效和安全性：一项系统评价和荟萃分析。
Clin Exp Med. 2025 Jul 9;25(1):239. doi: 10.1007/s10238-025-01794-w.
8
Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study.口服地西他滨和西扎珠苷联合维奈克拉治疗老年或身体不适的急性髓系白血病患者：一项2期研究。
Lancet Haematol. 2024 Apr;11(4):e276-e286. doi: 10.1016/S2352-3026(24)00033-4. Epub 2024 Mar 4.
9
A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.高危骨髓增生异常综合征和急性髓系白血病患者用维奈克拉治疗的真实土耳其经验。
Clin Lymphoma Myeloma Leuk. 2021 Aug;21(8):e686-e692. doi: 10.1016/j.clml.2021.04.004. Epub 2021 Apr 20.
10
A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort.每周一次的低剂量地西他滨和 venetoclax 方案在一个多种族队列中具有疗效且骨髓抑制毒性更低。
Blood. 2024 Nov 28;144(22):2360-2363. doi: 10.1182/blood.2024025834.

本文引用的文献

1
Myeloid NGS Analyses of Paired Samples from Bone Marrow and Peripheral Blood Yield Concordant Results: A Prospective Cohort Analysis of the AGMT Study Group.骨髓和外周血配对样本的髓系二代测序分析结果一致：AGMT研究组的前瞻性队列分析
Cancers (Basel). 2023 Apr 14;15(8):2305. doi: 10.3390/cancers15082305.
2
Clonal dynamics using droplet digital polymerase chain reaction in peripheral blood predicts treatment responses in myelodysplastic syndrome.利用外周血中的微滴式数字聚合酶链反应进行克隆动态分析可预测骨髓增生异常综合征的治疗反应。
Haematologica. 2023 Jul 1;108(7):1951-1956. doi: 10.3324/haematol.2022.281595.
3
The Minimal Residual Disease Using Liquid Biopsies in Hematological Malignancies.
血液系统恶性肿瘤中使用液体活检检测微小残留病
Cancers (Basel). 2022 Mar 3;14(5):1310. doi: 10.3390/cancers14051310.
4
Measurable Residual Disease Assessment as a Surrogate Marker in New Drug Development in Acute Myeloid Leukemia.基于可测量残留病灶评估的急性髓性白血病新药研发中的替代标志物。
Cancer J. 2022;28(1):73-77. doi: 10.1097/PPO.0000000000000572.
5
Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions.评估去甲基化药物联合其他疗法的临床试验：失败原因及潜在解决方案。
Clin Cancer Res. 2021 Dec 15;27(24):6653-6661. doi: 10.1158/1078-0432.CCR-21-2139. Epub 2021 Sep 22.
6
Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax.地西他滨联合维奈克拉治疗 TP53 突变急性髓系白血病的疗效。
Cancer. 2021 Oct 15;127(20):3772-3781. doi: 10.1002/cncr.33689. Epub 2021 Jul 13.
7
Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax.低甲基化剂联合 venetoclax 治疗急性髓系白血病中剪接突变的影响。
Blood Adv. 2021 Apr 27;5(8):2173-2183. doi: 10.1182/bloodadvances.2020004173.
8
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes.基线和连续分子谱分析预测低甲基化剂治疗骨髓增生异常综合征的结果。
Blood Adv. 2021 Feb 23;5(4):1017-1028. doi: 10.1182/bloodadvances.2020003508.
9
Mutational analysis of hematologic neoplasms in 164 paired peripheral blood and bone marrow samples by next-generation sequencing.通过二代测序对164对外周血和骨髓样本中的血液系统肿瘤进行突变分析。
Blood Adv. 2020 Sep 22;4(18):4362-4365. doi: 10.1182/bloodadvances.2020002306.
10
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.10天阿扎胞苷联合维奈克拉用于新诊断的不适合强化化疗以及复发或难治性急性髓系白血病的治疗：一项单中心2期试验
Lancet Haematol. 2020 Oct;7(10):e724-e736. doi: 10.1016/S2352-3026(20)30210-6. Epub 2020 Sep 5.